A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy

Biomaterials

Volumn 34, Issue 12, 2013, Pages 3042-3052

  Yuba, Eiji ^a   Harada, Atsushi ^a   Sakanishi, Yuichi ^b   Watarai, Shinobu ^a   Kono, Kenji ^a  

^a Osaka Prefecture University   (Japan)

^b DAICEL CORPORATION   (Japan)

Author keywords

Cancer immunotherapy; Cellular immunity; Cytoplasmic delivery; Dendritic cell; Membrane fusion; PH sensitive liposome

Indexed keywords

CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOPLASMIC DELIVERY; DENDRITIC CELLS; MEMBRANE FUSION; PH-SENSITIVE LIPOSOMES;

ANTIGENS; CELL MEMBRANES; DISEASES; MOLECULES; POLYMERS; TUMORS;

LIPOSOMES;

3 METHYLGLUTARYLATED POLY(GLYCIDOL)HYPERBRANCHED; 3 METHYLGLUTARYLATED POLY(GLYCIDOL)LINEAR; ANTIGEN; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; EGG YOLK PHOSPHATIDYLCHOLINE; GLYCIDOL; LIPOSOME; OVALBUMIN; PHOSPHATIDYLCHOLINE; POLYMER; PYRAN DERIVATIVE; PYRANINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG RELEASE; EGG YOLK; ENDOCYTOSIS; ENDOSOME; FEASIBILITY STUDY; FEMALE; IMMUNIZATION; LIPOSOMAL DELIVERY; MOLECULAR STABILITY; MOLECULE; MOUSE; NEOPLASM; NONHUMAN; PH; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CELL LINE; FEMALE; HYDROGEN-ION CONCENTRATION; IMMUNOTHERAPY; LIPOSOMES; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OVALBUMIN; POLYMERS; T-LYMPHOCYTES, CYTOTOXIC;

MURINAE; MUS;

EID: 84873432793     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.12.031     Document Type: Article

References (45)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
3. Fernadez N.C., Lozier A., Flament C., Ricciardi-Castagnoli P., Bellet D., Suter M., et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999, 5:405-411.
4. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5:296-306.
5. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
6. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002, 16:1217-1226.
7. Akagi T., Wang X., Uto T., Baba M., Akashi M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 2007, 28:3427-3436.
8. Yoshikawa T., Okada N., Oda A., Matsuo K., Mukai Y., Yoshioka Y., et al. Development of amphiphilic γ-PGA-nanoparticulate cytosolic protein delivery carrier. Biochem Biophys Res Commun 2008, 366:408-413.
9. Akagi T., Baba M., Akashi M. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine. Adv Polym Sci 2012, 247:31-64.
10. Bachelder E.M., Beaudette T.T., Broaders K.E., Freǐchet J.M.J., Albrecht M.T., Mateczun A.J., et al. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol Pharm 2010, 7:826-835.
11. Cui L., Cohen J.A., Broaders K.E., Beaudette T.T., Freǐchet J.M.J. Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting. Bioconj Chem 2011, 22:949-957.
12. Kunisawa J., Nakanishi T., Takahashi I., Okudaira A., Tsutsumi Y., Katayama K., et al. Sendai virus fusion protein mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system. J Immunol 2001, 167:1406-1412.
13. Yoshikawa T., Okada N., Tsujino M., Gao J.Q., Hayashi A., Tsutsumi Y., et al. Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma. Biol Pharm Bull 2006, 29:100-104.
14. Bungener L., Serre K., Bijl L., Leserman L., Wilschut J., Daemen T., et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002, 20:2287-2295.
15. Seki K., Tirrell D.A. pH-Dependent complexation of poly(acrylic acid) derivatives with phospholipid vesicle membrane. Macromolecules 1984, 17:1692-1698.
16. Murthy N., Robichaud J.R., Tirrell D.A., Stayton P.S., Hoffman A.S. The design and synthesis of polymers for eukaryotic membrane disruption. J Control Release 1999, 61:137-143.
17. Nakamura T., Moriguchi R., Kogure K., Shastri N., Harashima H. Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. Mol Ther 2008, 16:1507-1514.
18. Kono K., Igawa T., Takagishi T. Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivative. Biochim Biophys Acta 1997, 1325:143-154.
19. Sakaguchi N., Kojima C., Harada A., Kono K. Preparation of pH-sensitive poly(glycidol) derivatives with varying hydrophobicities: their ability to sensitize stable liposomes to pH. Bioconj Chem 2008, 19:1040-1048.
20. Frey H., Haag R. Dendritic polyglycerol: a new versatile biocompatible material. Rev Mol Biotechnol 2002, 90:257-267.
21. Yuba E., Harada A., Sakanishi Y., Kono K. Carboxylated hyperbranched poly(glycidol)s for preparation of pH-sensitive liposomes. J Control Release 2011, 149:72-80.
22. Shen Z., Reznikoff G., Dranoff G., Rock K.L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997, 158:2723-2730.
23. Moore M.W., Carbone F.R., Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988, 54:777-785.
24. Harding C.V., Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 1994, 153:4925-4933.
25. Li Y., Ke Y., Gottlieb P.D., Kapp J.A. Delivery of exogenous antigen into the major histocompatibility complex class I and class II pathways by electroporation. J Leukoc Biol 1994, 56:616-624.
26. Lutz M.B., Kukutsch N., Ogilvie A.L., Rössner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92.
27. Daleke D.L., Hong K., Papahadjopoulos D. Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim Biophys Acta 1990, 1024:352-366.
28. Yassine M.A., Lafleur M., Meier C., Petereit H.U., Leroux J.C. Characterization of the membrane-destabilizing properties of different pH-sensitive methacylic acid copolymers. Biochim Biophys Acta 2003, 1613:28-38.
29. Kono K., Henmi A., Yamashita H., Hayashi H., Takagishi T. Improvement of temperature-sensitivity of poly(N-isopropylacrylamide)-modified liposomes. J Control Release 1999, 59:63-75.
30. Hayashi H., Kono K., Takagishi T. Temperature-sensitization of liposomes using copolymers of N-isopropylacrylamide. Bioconjug Chem 1999, 10:412-418.
31. Mukherjee S., Ghosh R.N., Maxfield F.R. Endocytosis. Physiol Rev 1997, 77:759-803.
32. Chu C.J., Dijkstra J., Lai M.Z., Hong K., Szoka F.C. Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture. Pharm Res 1990, 7:824-834.
33. Yuba E., Kojima C., Harada A., Tana, Watarai S., Kono K. pH-Sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity. Biomaterials 2010, 31:943-951.
34. Albert M.L., Pearce S.F., Francisco L.M., Sauter B., Roy P., Silverstein R.L., et al. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998, 188:1359-1368.
35. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchel T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632.
36. Ke Y., Li Y., Kapp J.A. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses. Eur J Immunol 1995, 25:549-553.
37. Chapel H.M., August P.J. Report of nine cases of accidental injury to man with Freund's complete adjuvant. Clin Exp Immunol 1976, 24:538-541.
38. Mizuguchi H., Nakanishi T., Nakanishi M., Nakagawa T., Nakagawa S., Mayumi T. Intratumor administration of fusogenic liposomes containing fragment A of diphtheria toxin suppresses tumor growth. Cancer Lett 1996, 100:63-69.
39. Ishii K.J., Kawakami K., Gursel I., Conover J., Joshi B.H., Klinman D.M., et al. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus Interleukin-13 cytotoxin. Clin Cancer Res 2003, 9:6516-6522.
40. Mandal M., Lee K.D. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophy Acta 2002, 1563:7-17.
41. Shibata S., Okano S., Yonemitsu Y., Onimaru M., Sata S., Nagata-Takeshita H. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-β gene. J Immunol 2006, 177:3564-3576.
42. Faham A., Altin J.G. Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect. J Immunol 2010, 185:1744-1754.
43. Hayashi A., Wakita H., Yoshikawa T., Nakanishi T., Tsutsumi Y., Mayumi T., et al. A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity. J Control Release 2007, 117:11-19.
44. Altin J.G., Parish C.R. Liposomal vaccines-targeting the delivery of antigen. Methods 2006, 40:39-52.
45. Suzuki R., Oda Y., Utoguchi N., Namai E., Taira Y., Okada N., et al. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. J Control Release 2009, 133:198-205.